Companies › Kowa Company
1 active drug program in 1 registered trial: 1 Phase 4; Metabolic and endocrine; next expected readout Jul 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Pemafibrate Peroxisome proliferator-activated receptor alpha agonist | PPARA | Phase 4 | Hypercholesterolemia | Jul 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07634484 | Pemafibrate | Phase 4 | Hypercholesterolemia | Metabolic and endocrine | Jul 2027 |
Fresenius Kabi Renibus Therapeutics Chendu DIAO Pharmaceutical Group Azafaros Waterstone Pharmaceutical (Wuhan)
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.